Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides

Journal of the American Academy of Dermatology

Volumn 58, Issue 3, 2008, Pages 382-386

  Cen, Putao ^a   Duvic, Madeleine ^b,c   Cohen, Philip R ^b,c,d   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b University of Texas Health Science Center at Houston   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; ALPHA INTERFERON; BEXAROTENE; BORTEZOMIB; CA 27-29 ANTIGEN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; METHOTREXATE; MUCIN 1; PREDNISONE; TUMOR MARKER; VINCRISTINE; XIPAMIDE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLOOD LEVEL; CANCER RADIOTHERAPY; CHEMOLUMINESCENCE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CUTANEOUS T CELL LYMPHOMA; DISEASE ACTIVITY; ELECTRON THERAPY; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MALE; MYCOSIS FUNGOIDES; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PUVA; SEZARY SYNDROME; SKIN BIOPSY;

ADULT; AGED; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; FEMALE; HUMANS; MIDDLE AGED; MYCOSIS FUNGOIDES; NEOPLASM STAGING; PILOT PROJECTS; REMISSION INDUCTION; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 38949191987     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2007.12.014     Document Type: Article

References (26)

1. Diamandidou E., Cohen P.R., and Kurzrock R. Mycosis fungoides and Sézary syndrome. Blood 88 (1996) 2385-2409
2. Scarisbrick J.J. Staging and management of cutaneous T-cell lymphoma. Clin Exp Dermatol 31 (2006) 181-186
3. Diamandidou E., Colome M., Fayad L., Duvic M., and Kurzrock R. Prognostic factor analysis in mycosis fungoides/Sézary syndrome. J Am Acad Dermatol 40 (1999) 914-924
4. Diamandidou E., Colome-Grimmer M., Fayad L., Duvic M., and Kurzrock R. Transformation of mycosis fungoides/Sézary syndrome: clinical characteristics and prognosis. Blood 92 (1998) 1150-1159
5. Patton S., Gendler S.J., and Spicer A.P. The epithelial mucin, MUC1, of milk, mammary gland and other tissues. Biochim Biophys Acta 1241 (1995) 407-423
6. McGuckin M.A., Hurst T.G., and Ward B.G. Heterogeneity in production, secretion and glycosylation of MUC1 epithelial mucin by primary cultures of ovarian carcinoma. Int J Cancer 63 (1995) 412-418
7. Burchell J., Gendler S., Taylor-Papadimitriou J., Girling A., Lewis A., Millis R., et al. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res 47 (1987) 5476-5482
8. Croce M.V., Isla-Larrain M.T., Demichelis S.O., Gori J.R., Price M.R., and Segal-Eiras A. Tissue and serum MUC1 mucin detection in breast cancer patients. Breast Cancer Res Treat 81 (2003) 195-207
9. Gion M., Mione R., Leon A.E., Luftner D., Molina R., Possinger K., et al. CA27.29: a valuable marker for breast cancer management; a confirmatory multicentric study on 603 cases. Eur J Cancer 37 (2001) 355-363
10. Duvic M., Apisarnthanarax N., Cohen D.S., Smith T.L., Ha C.S., and Kurzrock R. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 49 (2003) 35-49
11. Duvic M., Lemak N.A., Redman J.R., Eifel P.J., Tucker S.L., Cabanillas F.F., et al. Combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 34 (1996) 1022-1029
12. Brossart P., Schneider A., Dill P., Schammann T., Grunebach F., Wirths S., et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res 61 (2001) 6846-6850
13. Brossart P., Heinrich K.S., Stuhler G., Behnke L., Reichardt V.L., Stevanovic S., et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93 (1999) 4309-4317
14. Paydas S., Sahin B., Gonlusen G., Hazar B., and Zorludemir S. MUC1 expression in plasmacytoma. Leuk Res 25 (2001) 221-225
15. Treon S.P., Maimonis P., Bua D., Young G., Raje N., Mollick J., et al. Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. Blood 96 (2000) 3147-3153
16. Takahashi T., Makiguchi Y., Hinoda Y., Kakiuchi H., Nakagawa N., Imai K., et al. Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient. J Immunol 153 (1994) 2102-2109
17. Ioannides C.G., Fisk B., Jerome K.R., Irimura T., Wharton J.T., and Finn O.J. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol 151 (1993) 3693-303
18. van de Wiel-van Kemenade E., Ligtenberg M.J., de Boer A.J., Buijs F., Vos H.L., Melief C.J., et al. Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J Immunol 151 (1993) 767-776
19. Chang J.F., Zhao H.L., Phillips J., and Greenburg G. The epithelial mucin, MUC1, is expressed on resting T lymphocytes and can function as a negative regulator of T cell activation. Cell Immunol 201 (2000) 83-88
20. Agrawal B., Krantz M.J., Reddish M.A., and Longenecker B.M. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med 4 (1998) 43-49
21. Agrawal B., Krantz M.J., Parker J., and Longenecker B.M. Expression of MUC1 mucin on activated human T cells: implications for a role of MUC1 in normal immune regulation. Cancer Res 58 (1998) 4079-4081
22. Agrawal B., and Longenecker B.M. MUC1 mucin-mediated regulation of human T cells. Int Immunol 17 (2005) 391-399
23. Zhang K., Sikut R., and Hansson G.C. A MUC1 mucin secreted from a colon carcinoma cell line inhibits target cell lysis by natural killer cells. Cell Immunol 176 (1997) 158-165
24. MacLean G.D., Reddish M.A., and Longenecker B.M. Prognostic significance of preimmunotherapy serum CA27.29 (MUC-1) mucin level after active specific immunotherapy of metastatic adenocarcinoma patients. J Immunother 20 (1997) 70-78
25. Heuser C., Ganser M., Hombach A., Brand H., Denton G., Hanisch F.G., et al. An anti-MUC1-antibody-interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumor cells. Br J Cancer 89 (2003) 1130-1139
26. Choi C., Witzens M., Bucur M., Feuerer M., Sommerfeldt N., Trojan A., et al. Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood 105 (2005) 2132-2134